SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

MLA

Roland B. Walter, et al. “SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial.” Blood, vol. 138, Nov. 2021, p. 3436. EBSCOhost, https://doi.org/10.1182/blood-2021-150277.

APA

Roland B. Walter, Krzysztof Brzózka, Stephen A. Strickland, Pau Montesinos, Simone Baldini, Milena Mazan, Andrea Pellacani, Niccolò Ravenni, Monica Binaschi, Francesco Bertolini, Farhad Ravandi, Giovanni Marconi, Sudipto Mukherjee, Susana Vives, Alessandro Bressan, Daniela Bellarosa, Alessandro Paoli, Scott R. Solomon, Dirk Laurent, … Salman Fazal. (2021). SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial. Blood, 138, 3436. https://doi.org/10.1182/blood-2021-150277

Chicago

Roland B. Walter, Krzysztof Brzózka, Stephen A. Strickland, Pau Montesinos, Simone Baldini, Milena Mazan, Andrea Pellacani, et al. 2021. “SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial.” Blood 138 (November): 3436. doi:10.1182/blood-2021-150277.